NEW YORK, Jul 31, 2012 (BUSINESS WIRE) -- Pfizer Inc. (NYSE:PFE) announced today top-line results from ORAL Start (A3921069), a Phase 3 study of the investigational agent tofacitinib, a novel, oral Janus kinase (JAK) inhibitor for the treatment of ...

On Tuesday July 31, one of the biggest names in the healthcare and drug manufacturing sector, Pfizer (PFE) will report earnings, and expectations are high.

Drug maker Pfizer Inc. (PFE) reported a 25% increase in second-quarter profit, as lower expenses helped cushion sales erosion from the loss of U.S.

Drug maker Pfizer Inc. (PFE ) on Tuesday posted better-than-expected second quarter earnings results, despite a continued slump in Lipitor cholesterol drug sales amid new generic competition.

Pfizer Inc.'s (PFE) second-quarter earnings rose 25% on lower expenses as the pharmaceutical giant continued to see sales of former anti-cholesterol blockbuster Lipitor slide amid competition from generic versions.

By MarketWatch. --Loss of market exclusivity for Lipitor cholesterol drug pressures results. --Second-quarter sales, profit exceed analysts' expectations.

(Reuters) - Pfizer Inc <PFE.N> reported higher-than-expected quarterly earnings, helped by cuts in research spending and other costs, and affirmed its 2012 profit forecast despite the negative impact of the stronger dollar.

Pfizer Inc. (PFE) (PFE), the world's largest drugmaker, said it will start a filing in mid-August to sell as much as 20 percent of its animal-health unit in an initial public offering.

By Tess Stynes. Pfizer Inc.'s (NYSE:PFE) second-quarter earnings rose 25% on lower expenses as the pharmaceutical giant continued to see sales of former anti-cholesterol blockbuster Lipitor slide amid competition from generic versions.